This week, we break down 5 pivotal regulatory decisions. This includes FDA actions for daridorexant in pediatric insomnia and a gene therapy for Huntington disease, alongside an accelerated approval ...

The bispecific EGFR- and MET-directed subcutaneous coformulation produced a 42% objective response rate in the phase 1b/2 OrigAMI-4 trial for patients with pretreated recurrent or metastatic HNSCC.

The Association of Rheumatology Professionals (ARP) has developed programming highlighting the perspectives of ...

A celebrity's recent multiple sclerosis misdiagnosis highlights the complexities of medical liability and the error in judgment defense.

Ursodeoxycholic acid recommended as first-line therapy and to prevent recurrence after liver transplant for PBC.

HealthDay News — Utah has become the first state to let an artificial intelligence (AI) program prescribe medication without a doctor writing the prescription, starting with acne treatments.

HealthDay News — A simple vaginal swab may one day help women with abnormal bleeding learn whether they have endometrial cancer without first going through a painful biopsy.

Higher treatment satisfaction, better treatment retention, and fewer adverse events reported for those choosing their treatment.

Results from the phase 3 VOCAL study demonstrate that oral vadadustat dosed 3 times per week successfully maintains hemoglobin levels vs standard ESA therapy in adult hemodialysis patients.

The designation is based on phase 2 data demonstrating dose-dependent increases in total sleep time among children and adolescents, including those with comorbid neurodevelopmental disorders.

Adults with moderately to severely active Crohn disease can now self-administer risankizumab induction at home using an ...

The Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for ifezuntirgene inilparvovec ...